SCHEMBL407156

SCHEMBL407156

CCOC(=O)CCNC(=O)c1ccc(/C(N)=N\O)cc1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
ITGB3 P05106 4/20 0.39
ITGA2B P08514 4/20 0.39
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C19 P33261 1/20 0.38
HDAC1 Q13547 1/20 0.37
HDAC2 Q92769 1/20 0.37
MTOR P42345 1/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
NPC1 O15118 1/20 0.37
F10 P00742 1/20 0.37
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
CHRM1 P11229 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL407157 1.00 MAPT (0.40) MAPTSMN1; SMN2MEN1KMT2AITGB3
SCHEMBL10283785 1.00 MAPT (0.40) MAPTSMN1; SMN2MEN1KMT2AITGB3
SCHEMBL406494 0.76 GAA (0.49) MAPTSMN1; SMN2MEN1KMT2ACYP1A2
SCHEMBL2805503 0.75 THRA (0.45) MAPTMEN1KMT2ACYP1A2NPC1
SCHEMBL2804388 0.75 THRA (0.45) MAPTMEN1KMT2ACYP1A2NPC1
SCHEMBL9968920 0.75 THRA (0.45) MAPTMEN1KMT2ACYP1A2NPC1
SCHEMBL2270307 0.75 ESRRG (0.53) MAPTSMN1; SMN2MEN1KMT2ACYP1A2
SCHEMBL3004909 0.74 CYP3A4 (0.48) MAPTSMN1; SMN2CYP1A2CYP3A4CYP2C19
SCHEMBL406864 0.73 KDM4E (0.47) MAPTSMN1; SMN2KMT2ACYP1A2CYP2C19
SCHEMBL406865 0.73 KDM4E (0.47) MAPTSMN1; SMN2KMT2ACYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2414341-B1 OXADIAZOLE DERIVATIVES MERCK SERONO SA (CH) 2017-09-13 EP disclosed
EP-2414342-B1 OXADIAZOLE DERIVATIVES MERCK SERONO SA (CH) 2017-05-31 EP disclosed
US-8815919-B2 Oxadiazole derivatives MERCK SERONO SA (CH) 2014-08-26 US disclosed
EP-2414341-A2 OXADIAZOLE DERIVATIVES Merck Serono SA (CH) 2012-02-08 EP disclosed
US-20120022109-A1 OXADIAZOLE DERIVATIVES MERCK SERONO SA (CH) 2012-01-26 US disclosed
WO-2010115751-A2 OXADIAZOLE DERIVATIVES MERCK SERONO S.A. (CH) 2010-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022109-A1 OXADIAZOLE DERIVATIVES OXA1L, HLA-DRB1, SSB MAPT 2597/4885SMN1; SMN2 599/4885MEN1 1228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.